CELZ creativemedicaltechnology.com Long-Term Loans to Capital Ratio

Creative Medical Technology (CELZ) minimizes capital expenditures by outsourcing medical trials to third-party contractors. This historical price chart reflects the asset's dynamics, with a value of 0.00. While the business is currently developing erectile dysfunction therapies, the expansion of research is temporarily increasing patent costs. Revenue is based on licensing cellular developments to specialized clinics treating joint and urological pathologies.

Creative Medical Technology is currently scaling its cell therapy platform for the treatment of strokes and erectile dysfunction in the US. This metric measures the proportion of long-term liabilities relative to equity, determining the company's financial leverage. The current value of 0.00 allows for an assessment of the issuer's solvency during periods of market turbulence. The dynamics of the long-term capital structure indicator reflect the balance between debt-funded R&D and financial stability. An upward trend in the curve may indicate either investments in development or an increase in the debt load.